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Background: Endothelial gene silencing via small interfering RNA (siRNA) transfection represents a promising strategy
for the control of vascular disease. Here, we demonstrate endothelial gene silencing in human saphenous vein using three
rapid siRNA transfection techniques amenable for use in the operating room.
Methods: Control siRNA, Cy5 siRNA, or siRNA targeting glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or
endothelial specific nitric oxide synthase (eNOS) were applied to surplus human saphenous vein for 10 minutes by (i)
soaking, (ii) applying 300 mmHg hyperbaric pressure, or (iii) 120 mmHg luminal distending pressure. Transfected vein
segments were maintained in organ culture. siRNA delivery and gene silencing were assessed by tissue layer using confocal
microscopy and immunohistochemistry.
Results:Distending pressure transfection yielded the highest levels of endothelial siRNA delivery (22% pixels fluorescing)
and gene silencing (60% GAPDH knockdown, 55% eNOS knockdown) as compared with hyperbaric (12% pixels
fluorescing, 36% GAPDH knockdown, 30% eNOS knockdown) or non-pressurized transfections (10% pixels fluorescing,
30% GAPDH knockdown, 25% eNOS knockdown). Cumulative endothelial siRNA delivery (16% pixels fluorescing) and
gene silencing (46% GAPDH knockdown) exceeded levels achieved in the media/adventitia (8% pixels fluorescing, 24%
GAPDH knockdown) across all transfection methods.
Conclusion:Endothelial gene silencing is possible within the time frame and conditions of surgical application without the
use of transfection reagents. The high sensitivity of endothelial cells to siRNA transfection marks the endothelium as a
promising target of gene therapy in vascular disease. ( J Vasc Surg 2010;52:1608-15.)
Clinical Relevance: Vein bypass graft failure due to intimal hyperplasia and restenosis continues to be an obstacle to
long-term vein graft durability. Currently, there are no agents available that can be applied to vein grafts to reduce the rate
of failure. This work demonstrates the feasibility of intraoperative siRNA therapeutics directed at the endothelium. If
developed further, siRNA cocktails could be designed that provide a protective effect by silencing endothelial gene
expression that leads to intimal hyperplasia. In addition, endothelial gene silencing could be used to induce favorable
effects on the vasculature in other realms of vascular surgery.Gene silencing by small interfering RNA (siRNA) trans-
fection holds promise for the control of vascular disease.1,2 In
one extension of vascular RNA interference technology, vein
grafts could be treated at the time of surgery with siRNA
cocktails designed to interrupt the signaling pathways leading
to intimal hyperplasia, stenosis, and graft failure.3 Our group
recently demonstrated the first transfection of human saphenous
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substrate (MARCKS), a gene product shown to reduce intimal
hyperplasia by inhibiting smoothmuscle cell migration and pro-
liferation when silenced.2 However, these data, as well as an
earlier in vitro study, revealed a heightened susceptibility of en-
dothelial cells to siRNA transfection and gene silencing com-
pared with other vascular cells.1,2 Given the inciting role of
endothelial cells in the pathogenesis of vascular disease, the en-
dothelium is an ideal target of vascular gene therapy.4-6 In this
study, we further characterize ex vivo siRNA delivery and gene
silencing in human saphenous vein endothelium, comparing
both pressurized and non-pressurized delivery methods amena-
ble for use in the operating room.
We employ three noninvasive techniques for the local
administration of siRNA to human saphenous vein suitable
for surgical application. These techniques involve soaking
vein in siRNA solution without the use of pressure or
transfection reagents, soaking vein in siRNA solution in the
presence of 300mmHghyperbaric pressure using a custom
fabricated pressure chamber, or distending vein segments
with siRNA solution at 120 mm Hg luminal distending
pressure. Hyperbaric transfection is designed to be analo-
gous to the nondistending external pressure technique
described by Mann and colleagues for DNA oligonucleo-
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identified.7 Distending pressure transfection was used by
our group for MARCKS silencing in human saphenous
vein2 and utilizes a pressure level intended not to exceed
the pressures experienced by vein grafts after implantation
into the arterial circulation or pressures where graft injury
has been shown to occur.8-10 The genes chosen for
silencing are glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) and endothelial specific nitric oxide syn-
thase (eNOS). GAPDH is an abundant housekeeping gene
expressed ubiquitously by all cells in the vessel wall. eNOS
is an endothelial-specific gene product found only in the
endothelium.11
MATERIALS AND METHODS
siRNA design. Control siRNA (sense 5’ - CGC ACC
AGA ACA AAC ACA C - 3’), Cy5 siRNA (sense 5’ - Cy5 -
CGCACCAGAACAAACACAC - 3’), and eNOS siRNA
(sense 5’ - CGA GGA GAC UUC CGA AUC UUU - 3’)
were purchased from Dharmacon (Lafayette, CO) as de-
scribed previously.1 GAPDH siRNA (Silencer GAPDH
siRNA -Human) was purchased from Ambion (proprietary
sequence; Austin, Tex). Control and Cy5 siRNA sequences
do not harbor any homology with the human genome.
siRNA transfection of human saphenous vein.
Freshly harvested surplus human saphenous vein was pro-
cured from the operating room with institutional review
board approval from patients undergoing cardiac or vascu-
lar procedures. Vein tissue was transported to the labora-
tory in Plasmalyte A solution (140 mEq/L sodium, 5
mEq/L potassium, 3 mEq/L magnesium, 98 mEq/L
chloride, 27 mEq/L acetate, 23 mEq/L gluconate, 294
mOsmol/L, pH 7.4) for immediate transfection. Speci-
mens were divided into 3 to 4 cm segments and transfected
with siRNA resuspended in Plasmalyte A by soaking seg-
ments for 10 minutes in siRNA solution in the absence of
pressure, soaking vein segments in siRNA solution for 10
minutes in the presence of 300 mm Hg (1 mm Hg  133
Pa) hyperbaric pressure, or distending vein segments with
siRNA solution for 10 minutes at 120 mm Hg luminal
distending pressure. For the soak treatment, vein segments
were submerged in 500 L siRNA solution in the wells of
24-well plates. For hyperbaric pressure transfection, vein
segments were submerged in 500L siRNA solution in the
wells of 24-well plates, with the plates then placed in a
custom fabricated pressure chamber (Fig 1) and the pres-
sure in the chamber raised to 300 mm Hg using wall air.
For distending pressure transfection, 3 to 4 cm vein seg-
ments were cannulated distally using a vein graft cannula
secured with 3-0 silk ties, and flushed with siRNA solution.
The veins were then clamped proximally using a spring-
loaded crossover clamp (bulldog clamp), and siRNA solu-
tion was infused via the cannula to a pressure of 120 mm
Hg using a standard angioplasty insufflator.7 After all trans-
fections, vein segments were rinsed, divided into 5 to 10
mm segments, and placed in organ culture consisting of
Roswell Park Memorial Institute 1640 media supple-
mented with 30% fetal bovine serum, 2 mM L-glutamine,100 IU/mL penicillin, 100 g/mL streptomycin, and
0.25 g/mL amphotericin B with media changes per-
formed every 2 days, as previously described.12,13 Prelimi-
nary dose-response experiments achieved eNOS and
GAPDH mRNA and protein knockdown in whole vein
homogenate by quantitative real time polymerase chain
reaction and Western blotting using 25 M siRNA and a
10 minute soak treatment. Immunohistochemistry experi-
ments were then performed using 25 M control,
GAPDH, and eNOS siRNA to evaluate gene knockdown
by tissue layer and transfection method.
Confocal microscopy. Confocal microscopy to assess
Cy5 siRNA delivery was performed as previously de-
scribed.2 Briefly, cultured vein segments transfected with
25 M Cy5 siRNA were snap-frozen after 24 hours in
organ culture, sectioned, mounted, and imaged under con-
focal microscopy. Micrographs with excitation wavelengths
for red, green, and blue fluorescence emission were ac-
quired to showCy5 fluorescence (blue), as well as the vessel
architecture (green and red auto-fluorescence of the elastic
fibers). Cy5 fluorescence in confocal micrographs was ana-
lyzed using Adobe Photoshop CS2 (Adobe Systems, San
Jose, Calif) to quantify the percentage of pixels fluorescing
in a given area, as previously described.14
Immunohistochemistry. Vein segments transfected
with control or GAPDH siRNA were cultured for 5 days,
formalin fixed, and embedded in paraffin. Serial sections
were stained with anti-GAPDH (AM4300; Ambion), anti-
CD31 (ab9498; Abcam, Cambridge, Mass) or anti-actin
(A4700; Sigma, St. Louis, Mo) antibodies according to
manufacturers’ protocols. Vein segments transfected with
control or eNOS siRNAwere cultured for 0, 1, 2, or 3 days.
Serial sections were fixed with acetone and stained with
anti-eNOS (610291; BD Transduction Laboratories, San
Jose, Calif) or anti-CD31 antibodies.
For assessment of GAPDH knockdown, quantitative
morphometric analysis was performed to cover the entire
cross-sectional area of the vein segments. Images were
analyzed using Adobe Photoshop CS4 (Adobe Systems) to
quantify pixels with DAB chromagen luminosity.14-16 The
Fig 1. Custom pressure chamber designed to expose standard
tissue culture plates to hyperbaric pressure.total area in pixels for the media and adventitia was deter-
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selected according to hue, color intensity, and saturation,
discriminating unstained portions of the specimen using
the Magic Wand tool with the Select Similar function.17
Results were calculated as total pixels stained divided by
media and adventitial pixel area and standardized to global
actin staining in the media and adventitia. Next, the endo-
thelial area was manually selected using the Lasso tool,
inverted, and the non-endothelial area deleted. Stained
endothelial pixels were divided by total endothelial pixels
and standardized to CD31 staining. Assessment of eNOS
knockdown in the endothelial layer was performed in the
same manner and standardized to CD31 staining.
Statistical methods. All experiments are representa-
tive of a cohort of three patient samples per group unless
otherwise noted. Data are presented as mean  standard
deviation. Statistical analysis was performed using STATA
software (STATA Corporation, College Station, Tex). Sig-
nificance of association was assessed using one-way analysis
of variance (ANOVA) with Bonferroni correction (Fig 2),
unmatched two-way ANOVA with Bonferroni correction
(Fig 3), or repeated measures two-way ANOVA with Bon-
ferroni correction (Fig 4).
RESULTS
Endothelial siRNA delivery exceeds medial and ad-
ventitial delivery and is increased using distending pres-
sure transfection. Confocal micrographs of vein segments
maintained in organ culture for 24 hours following 10
minute siRNA transfections with 25 M Cy5 siRNA dem-
onstrated discrete areas of blue Cy5 fluorescence within all
tissue layers (Fig 2, A).
Quantitation of blue fluorescence in micrographs using
image analysis software demonstrated significantly greater
uptake of Cy5 siRNA in the endothelial layer using distend-
ing pressure transfection as compared to the soak or hyper-
baric transfection treatments (Fig 2, B; P  .05 for the
difference between distending pressure transfection
[22%  11% pixels fluorescing] vs soak [10%  6% pixels
fluorescing] or hyperbaric [12%  9% pixels fluorescing]
treatments). Quantitative analysis of medial, adventitial,
and total vessel Cy5 fluorescence statistically failed to dem-
onstrate additional differences in siRNA delivery between
the three transfection methods. However, trends for
greater medial layer and total vessel delivery after distend-
ing pressure transfection (Fig 2, C and E), as well as greater
adventitial delivery after hyperbaric pressure transfection
(Fig 2, D), were observed. Cumulative data from all trans-
fection images revealed significantly greater uptake of
siRNA by the endothelial layer as compared with the media
and adventitia (Fig 2, F; P .05 for the difference between
endothelial delivery [16% 8% pixels fluorescing] vs medial
[9% 6% pixels fluorescing] or adventitial delivery [6% 5%
pixels fluorescing]).
Endothelial GAPDH knockdown exceeds medial
and adventitial GAPDH knockdown and is increased
using distending pressure transfection. To assess pro-
tein knockdown levels throughout the vessel wall afterrapid siRNA transfection, vein segments were transfected
with siRNA targeting the ubiquitous metabolic enzyme
GAPDH using all three transfection methods. GAPDH
protein expression was quantified by immunohistochemis-
try after 5 days in organ culture. Distending pressure
transfection produced the greatest degree of GAPDH
knockdown in all tissue layers (Fig 3,A panels a-b). Gene
silencing was specific to GAPDH and not indicative of
global protein degradation as CD31 and actin levels were
maintained (Fig 3, A panels c-f). In the endothelium,
distending pressure achieved a 60%  13% reduction in
GAPDH protein levels followed by hyperbaric (36% 
4%), and non-pressurized transfection (30%  9%; Fig 3,
B; P  .05 for all). In the media/adventitia, distending
pressure achieved a 36% 9% reduction in target protein
levels (Fig 3, C; P  .05), whereas hyperbaric and non-
pressurized transfection did not significantly reduce
GAPDH protein. Cumulative analysis of images from all
transfection methods demonstrated heightened GAPDH
knockdown in the endothelial layer compared to the me-
dia/adventitia (Fig 3, D; P  .05 for endothelial pixels
stained [46%  13%] vs medial/adventitial pixels stained
[24%  9%]).
eNOS knockdown is achieved using all three trans-
fection methods and is increased using distending pres-
sure transfection. To further confirm endothelial gene
silencing in human saphenous vein using rapid siRNA
transfection, vein segments were transfected with siRNA
targeting eNOS, a gene product found only within the
endothelium. eNOS protein expression was quantified by
immunohistochemistry after 0 to 3 days in organ culture.
eNOS knockdown was achieved using all three transfection
methods and was greatest using distending pressure trans-
fection (Fig 4, A panels a-b). Gene silencing was specific to
eNOS and not indicative of global protein degradation as
CD31 levels were maintained (Fig 4, A panels c-d). At day
3, eNOS knockdown levels reached 25%  6% for non-
pressurized, 30%  10% for hyperbaric, and 55%  6% for
distending pressure transfection (Fig 4, B-D; P  .05 for
all). Distending pressure transfection produced signifi-
cantly greater eNOS knockdown than the other two meth-
ods (Fig 4, E; P  .05).
DISCUSSION
Previous work from our group reported an increased
susceptibility of human endothelial cells to siRNA transfec-
tion and gene silencing in vitro using lipid transfection
reagents,1 as well as greater siRNA delivery to the endothe-
lium in human saphenous vein segments transfected ex vivo
using distending pressure.2 This study now confirms the
feasibility of intraoperative vascular gene therapy directed
towards the endothelium by demonstrating robust endo-
thelial gene silencing of globally expressed and endothelial-
specific gene products in intact human saphenous vein
transfected using rapid siRNA transfection techniques.
This study compares three methods for rapid siRNA
delivery that could be used in the operating room. The
simplest transfection method would entail incubating vein
JOURNAL OF VASCULAR SURGERY
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administration of naked siRNA to solid tissues without the
use of transfection reagents or pressure has been shown in
other systems, including the eye, lung, central nervous
system, and tumors, with comparable levels of gene silenc-
ing between 40% and 75% achieved in experimental ani-
mals.18,19 Conversely, the initial report by Mann and col-
Fig 2. Endothelial siRNA delivery exceeds medial and
transfection. (A) Vein segments transfected with Cy5 siR
dent of the red/green autofluorescence of the elastic fib
pixels by tissue layer demonstrates (B) maximal Cy5 flu
transfection as compared with the soak and hyperbaric pr
(C-E) Cy5 fluorescence in themedial layer, adventitial lay
three transfection conditions. (F) Cumulative analysis of
Cy5 fluorescence in the endothelial layer as compared to t
For all data, n  5 to 6 vein segments per condition.leagues demonstrating oligodeoxynucleotide (ODN)transfection of human vein indicated minimal ODN deliv-
ery and noODN activity in vein transfected without the use
of pressure.7 This apparent discrepancy between siRNA
and ODN delivery could be explained by a heightened
activity of siRNA versus ODN20 or by the existence of cell
surface receptors that assist in siRNA uptake from the
environment.21 Methodological differences could also
titial delivery and is increased using distending pressure
emonstrate discrete areas of blue fluorescence indepen-
epresentative micrograph, 600). Quantitation of blue
ence in the endothelium after distending pressure (DP)
e (HBP) transfections (*P .05 for both comparisons).
d total vessel wall was statistically equivalent between the
es from all transfection conditions demonstrates greater







he mcomplicate the comparison between siRNA and ODN de-
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detected with a nuclear counterstain, whereas siRNA local-
izes and functions in the cytoplasm. However, other inves-
tigators have achieved high levels of ODN delivery to both
porcine and human vein using non-pressurized transfec-
tion, suggesting the uptake of DNA and RNA oligonucle-
otides by vein may proceed in a similar fashion.22,23
Hydrodynamic pressure transfection with siRNA has
been performed in liver, muscle, kidney, lung, and pancre-
atic tissues producing gene silencing levels as high as 90% in
the liver.19Hyperbaric and distending pressure transfection
Fig 3. Endothelial glyceraldehyde-3-phosphate dehydr
adventitial GAPDH knockdown and is increased using
demonstrates GAPDH knockdown within all tissue laye
siRNA (panel b) as compared to vein segments treated w
GAPDH as CD31 (panels c,d) and actin (panels e,f)
GAPDH knockdown in the endothelium using distend
pressurized (soak) transfection. (C) Medial/adventitial
pressure transfection, but not with hyperbaric or no
transfections revealed greater knockdown in the endot
segments per condition. Micrographs (400) correspond
(* denotes P  .05 for comparisons).are more complex than non-pressurized transfection; how-ever, both have been used successfully for the preparation
of vein bypass grafts in the operating room.24-26 Advan-
tages to these methods suggested by our data include
greater siRNA delivery and protein knockdown, consistent
with results reported from other tissue types using pressure.
The tissue layer delivery patterns uncovered also appear to
logically follow from the mechanism of pressure delivery.
Distending pressure transfection places the endothelial cell
at the forefront of the pressure gradient and led to the
highest delivery in the endothelium, followed by the media
and the adventitia. Hyperbaric transfection exposes both
ase (GAPDH) protein knockdown exceeds medial and
ding pressure transfection. (A) Immunohistochemistry
er distending pressure (DP) transfection with GAPDH
ntrol siRNA (panel a). Protein knockdown is specific to
are preserved. Quantitation demonstrates (B) greater
ressure as compared with hyperbaric (HBP) and non-
DH levels were significantly reduced after distending
ssurized transfection. (D) Cumulative analysis of all
as compared with the media/adventitia. n  3 vein









to osides of the vessel wall to elevated pressure equally and
ents
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and adventitial surfaces in direct contact with the siRNA
solution. Nonetheless, these data suggest differing trans-
fection patterns produced by the various techniques, and
the final choice of transfection method could be selected
Fig 4. Endothelial specific nitric oxide synthase (eNOS
and is increased using distending pressure transfection. (
eNOS knockdown after distending pressure (DP) tran
segments treated with control siRNA (panel a). Protein k
preserved. (B-E) Quantitation demonstrates greater eN
hyperbaric (HBP) and non-pressurized (soak) transfectio
correspond to one representative image of three experimand optimized to match the pattern and degree of silenc-ing desired for different target genes throughout the
vessel wall.
This study does not directly explore cell viability or
vessel damage induced by the various transfectionmethods,
although global cellular protein expression as evidenced by
ckdown is achieved using all three transfection methods
munohistochemistry demonstrates greatest endothelial
on with eNOS siRNA (panel b) as compared to vein
down is specific to eNOS as CD31 levels (panels c,d) are
knockdown using distending pressure as compared to
 3 vein segments per condition. Micrographs (400)





n. nhousekeeper gene levels remained stable after transfection.
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after distending veins to pressures as high as 500 mm Hg
during graft preparation when using a warm nutritive me-
dium and papaverine.10 However, other authors demon-
strated morphologic vessel damage after distending grafts
to 500 and 600 mm Hg during preparation.8,9 The hyper-
baric transfection technique was used in the PRoject of Ex-
vivoVein graft ENgineering viaTransfection (PREVENT) III
and PREVENT IV clinical trails of edifoligide for vein graft
protection.24,25 Despite demonstration of safety in phase II
testing,27 the rate of graft failure in veins pressure-treated
with placebo in the PREVENT IV trial was found to be
higher than in other studies, and the transfection technique
was questioned to have heightened the rate of vein graft
failure.28 Given these conflicting reports, the possibility of
vessel damage from pressure transfection remains, and rig-
orous testing of transfection techniques is warranted before
future clinical trials.
Gene silencing levels in this study ranged from 25% to
60%, depending on the transfection method and gene
targeted. Quantitative immunohistochemistry suggested
greater protein knockdown at delayed time points, consis-
tent with prior data.1 Although further optimization of
transfection methods could strive to fully silence any tar-
geted gene, the gene silencing levels achieved thus far are
comparable with other reports of gene silencing in solid
tissues.18 Furthermore, phenotypic relief from disease has
been shown in experimental models following targeted
gene silencing as low as 40%, suggesting RNAi-based ther-
apeutics could be successful at alleviating disease with less
than 100% suppression of involved genes.2,29
In this study, tissue layer gene knockdown levels are
measured by immunohistochemistry without confirmatory
assessment of mRNA knockdown. However, prior studies
from our group rigorously demonstrated the relationship
between mRNA silencing and protein knockdown in vitro
in both human endothelial and smooth muscle cells.1 Con-
firmation of mRNA knockdown by tissue layer would re-
quire quantitative in situ hybridization or laser capture
microdissection of cell populations from each distinct tissue
layer followed by quantitative real time polymerase chain
reaction. These experiments are challenging to perform
using operative tissue samples in limited supply. This study
is similarly limited by small sample sizes for each of the
experimental conditions, owing to the challenges of obtain-
ing appreciable quantities of human vein from surgical
patients in a timely manner. Despite these disadvantages,
use of human vein tissue in these early studies will ease the
transition from bench to bedside as the technology will
have proven successful in vein tissue from the full range of
patients undergoing bypass operations. Nonetheless, the ex
vivo transfection of vein, while an important prerequisite
step before further study, fails to provide insight into the
time course, degree of gene silencing, and phenotypic
effects on vein graft remodeling that would be achieved in
veins grafted into a physiologic flow environment. Thus,further experimentation with siRNA transfection of vein
grafts in animal models is justified by this study.
To conclude, here we demonstrate the feasibility of
siRNA delivery and gene silencing in human vein endothe-
lium within the timeframe and conditions of surgical appli-
cation. The high sensitivity of endothelial cells to gene
silencing marks the endothelium as a promising target of
intraoperative vascular gene therapy. Distending pressure
transfection produced the greatest degree of siRNA deliv-
ery and protein knockdown, although various transfection
methods are available and could be optimized on a case-by-
case basis to intelligently manipulate target gene expression
within the different layers of the vessel wall.
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